Skip to main content
Clinical Trials/NCT04525534
NCT04525534
Terminated
Not Applicable

Plasma Concentration of Biological Markers in Placenta Spectrum

University of Arkansas0 sites19 target enrollmentAugust 30, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Placenta Accreta
Sponsor
University of Arkansas
Enrollment
19
Primary Endpoint
Determine the level of placental-derived MPs (Microparticles/mL)
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this exploratory study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with placenta accreta spectrum (PAS) at the time of cesarean delivery in women with suspected PAS compared to women without PAS. Our aim is to determine if women with PAS have a unique MP and protein signature at the time of delivery compared with women without PAS.

Detailed Description

Maternal blood samples will be taken at various points during the intrapartum period. A healthy group of women admitted for delivery will act as a matched control and will have their blood sampled at similar time points. The primary outcome variables will include the total number of micro-particles, the number of micro-particles from each cell line (platelet, placental, endothelial etc.), and protein markers The knowledge gained from this study has the potential to develop a diagnostic test for PAS with the ability to improve management and outcomes for mother and baby through earlier diagnosis.

Registry
clinicaltrials.gov
Start Date
August 30, 2020
End Date
July 10, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18 - to 45-years old, inclusive
  • Suspected or confirmed PAS or phenotypically matched controls
  • Delivery by cesarean section
  • Gestational age greater than 28 weeks
  • Singleton pregnancy

Exclusion Criteria

  • Intrauterine fetal demise,
  • Severe fetal anomalies (infant not expected to survive)
  • Emergent cesarean delivery

Outcomes

Primary Outcomes

Determine the level of placental-derived MPs (Microparticles/mL)

Time Frame: Up to 6 hours

Determine quantitatively the level of placental-derived MPs which may be altered in 10 subjects with PAS and 10 phenotypically-matched controls.

Identify biomarkers (picogram/mL)

Time Frame: Up to 6 hours

Determine quantitatively the level of biomarkers which may be altered in 10 subjects with PAS and 10 phenotypically-matched controls.

Secondary Outcomes

  • Is there a correlation between maternal serum total placental MPs and biomarkers to the International Federation of Gynecology and Obstetrics (FIGO) classification for PAS at the time of cesarean delivery.(Up to 6 hours)

Similar Trials